PreludeDx is the leading personalized breast cancer diagnostics company dedicated to improving outcomes for patients diagnosed with DCIS (Ductal Carcinoma in Situ). The company provides patients and physicians with evidence-based tools to improve patient outcomes and reduce the cost to the healthcare system by helping to ensure women are not over or under treated. For women diagnosed with DCIS, PreludeDx provides a patented molecular test (DCISionRT®) that predicts a woman’s personal likelihood or risk of developing DCIS recurrence in 10 years and invasive breast cancer in 10 years with or without adjuvant radiation therapy after breast conserving surgery. Visit PreludeDx.com


Live chat

Description
PreludeDx Introduction
An introduction to PreludeDx - who we are, what we do, why we do it.
Patient Information and FAQs
Patient Brochure
DCIS Patient Counseling Tool
Test Requisition Form
Publications
Contact Us
Contact Customer Care
Resources